Late of Pharmalot -- and highly-expert in the pharma sector -- now at InVivo Blog, he offers this -- but do go read it all. Good to see he's back, and in fine form, on Schering-Plough/Merck (with his own great "Boss" graphic, to boot!):
. . . .There was, however, no mention of any role for Fred Hassan, the perennially upbeat Schering-Plough chief executive. Perhaps if Merck's board really wants to make good on its contention that this is a reverse merger, the top job will be handed over. Dick Clark, Merck's chief executive, could finish his career comfortably as chairman. Whether investors would be pleased is another matter. But there's no arguiing that would push the managerial change beyond 40 percent in a very symbolic way. . . .
Hilarious!
Reference:
The IN VIVO Blog: Is it Merck or is it Schmerck?
2 comments:
See also:
"Merck to Bride: Leave the Jewelry at Home"
Brian Orelli's offering, today on the topic above, over at the Motley Fool.
Namaste
"Meanwhile, even though the wedding details are almost complete, investors may have to wait awhile to know whether the purchase was a good investment for Merck. Unlike the Pfizer (NYSE: PFE)-Wyeth (NYSE: WYE) deal, which seemed to be mostly driven by cost-saving synergies, Schering's pipeline was a big driver for this purchase -- and the pipeline will take some time to have an impact on revenue."
This is echoed by SP.
http://www.schering-plough.com/news/news_article.aspx?reqid=1325856
However a few years ago SP didn't have a late stage pipeline.
http://www.chartsbank.com/DrugPipelineNewDetail.aspx?NewsID=11
That is until it bought Organon.
http://www.genengnews.com/news/bnitem.aspx?name=14136830
Of which Suggamadex has had problems, but asenapine, the main driveer, has just been approved.
Although you never can tell. Over on Cafepharma they're already pretty down on the sales potential of this latest compound.
Salmon
Post a Comment